News

Biofuels producers join forces
Enlarge image

PolicyBelgiumEUGermanyItalyUKFinland

Biofuels producers join forces

11.02.2013 - Seven leading producers of second generation biofuels have joined forces in an industry initiative to support uptake of their technology.

The initiative, named “Leaders of Sustainable Biofuels”, aims at supporting the development of second generation biofuels as a sustainable alternative to fossil fuels in Europe. The leaders of Chemtex, British Airways, BTG, Chemrec, Clariant, Dong Energy and UPM are joining forces to ensure the market uptake of advanced sustainable biofuels by all transport sectors. The Chief Executive Officers of the companies suggested biofuels were cost-competitive and had less environmental impact than fuels made from oil or natural gas. They argue that second-generation biofuels can reduce GHG emissions by at least 65%.

In contrast, first generation biofuels, made from corn, wheat, soy or palm provide only modest reductions in greenhouse gases and can push up food prices. At the initiative’s launch in Brussels, the “Leaders of Sustainable Biofuels” demanded to accelerate research and innovation into emerging biofuel technologies, including algae and new conversion pathways, supported by public and private R&D programmes. They said it were important to develop worldwide accepted sustainability certification and to establish financing structures to facilitate the implementation of sustainable biofuel projects. The initiative aims at promoting the benefits of advanced sustainable biofuels and to address national policy makers, the European Commission and the European Parliament. The “Leaders are convinced that their biofuels are key for the reduction of fossil energy imports in the EU”. 

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/biofuels-producers-join-forces.html

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR30.9%
  • CO.DON3.13 EUR26.2%
  • FORMYCON8.03 EUR17.7%

FLOP

  • CYTOS0.19 CHF-24.0%
  • ADDEX3.13 CHF-21.4%
  • EVOTEC3.06 EUR-18.2%

TOP

  • SANTHERA88.65 CHF2088.9%
  • PAION3.18 EUR238.3%
  • CO.DON3.13 EUR229.5%

FLOP

  • CYTOS0.19 CHF-95.1%
  • 4SC1.06 EUR-45.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 29.09.2014